Shanghai Bioheart (2185.HK) Q4 2025 Earnings Report

Shanghai Bioheart reported a challenging Q4 2025, characterized by a sharp drop in profitability driven by a continued and front-loaded R&D push. Revenue for Q4 2025 was 23.67 million CNY, with gross profit a negative 2.05 million CNY and an operating loss of 49.62 million CNY. Net income amounted to a loss of 42.13 million CNY, and EBITDA was negative 39.39 million CNY, reflecting an EBITDA margin of -1.66x. The company’s liquidity profile remains robust, with total cash and short-term investments of 248.63 million CNY and a net debt position of -79.59 million CNY, suggesting substantial cushion to fund ongoing development activities. Administrative and selling expenses for the quarter were not fully disclosed beyond SG&A of 7.58 million CNY, but total operating expenses stood at 47.57 million CNY, underscoring a heavy burn tied to R&D and pipeline progression. Management commentary is not included in the dataset, but the quarter’s results imply a continued emphasis on product development (Bioheart BRS, Iberis 2nd) and potential collaboration outcomes (notably with Terumo China) as key catalysts for future value realization. Investors should monitor clinical milestones, regulatory progress, and any capital-raising activities as near-term drivers of profitability and liquidity.